Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis

Hermann, Juliana Sato; Weckx, Lily Yin; Nurmberger, J M; Santos, Gildo; Pignatari, Antônio Carlos Campos; Pignatari, Shirley Shizue Nagata

doi:10.1016/j.ijporl.2016.01.032

Cited by 40 publications

(25 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatments include the use of acyclovir; intralesional cidofovir; CO 2 laser; microdebridement; argon plasma coagulation and interferon‐α; the results are variable . Gardasil (Merck Sharp & Dohme Corp, West Point, EUA), the quadrivalent HPV (types 6, 11, 16, and 18) vaccine was tested as a treatment for JLP and did not produce significant effects to improve the course of the disease . There are scales that help with both planning and in evaluating the efficacy of treatments, based on the severity of the disease, for example, Voice Handicap Index‐10 (VHI‐10), Roughness, Breathiness, Asthenia, Strain (GRBAS), and the laryngoscopic score of Derkay et al (1998) .…”

Section: Introductionmentioning

confidence: 99%

“…[5][6][7] Gardasil (Merck Sharp & Dohme Corp, West Point, EUA), the quadrivalent HPV (types 6, 11, 16, and 18) vaccine was tested as a treatment for JLP and did not produce significant effects to improve the course of the disease. 8 There are scales that help with both planning and in evaluating the efficacy of treatments, based on the severity of the disease, for example, Voice Handicap Index-10 (VHI-10), 9 Roughness, Breathiness, Asthenia, Strain (GRBAS), 10 and the laryngoscopic score of Derkay et al (1998). 11 A systematic study demonstrated that the Derkay laryngoscopic scale is ranked the second most used in studies of LP, and that the visual method is used most frequently.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Histopathological features of juvenile‐onset laryngeal papillomatosis related to severity

Achkar

Duarte

Carlos³

et al. 2019

Head & Neck

View full text Add to dashboard Cite

Background Laryngeal papillomatosis (LP) is a disease that presents in both juvenile (JLP) and adult patients (ALP). This study correlated papillomatosis characteristics with the Derkay score. Methods Retrospective data and biopsies of 36 patients with JLP and 56 with ALP were collected and separated into groups according to their scores. Results The mean of the Derkay score, in the JLP group was 10.97 and in Group ALP was 8.26. The JLP group presented a more aggressive result than in the adult group (P = .02). In the JLP group, the respiratory difficulty (P = .01) and tracheostomy were correlated to a higher Derkay score (P < .05). Microscopically, the JLP samples presented a higher incidence of atypical mitosis and mitosis above the basal cells layer of the epithelium (P < .05) and these characteristics were correlated with a higher Derkay index (P = .03). Conclusion Findings suggest that ALP and JLP can present different clinical courses and histopathological features. There was a higher degree of LP severity in JLP.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Histopathological features of juvenile‐onset laryngeal papillomatosis related to severity

Achkar

Duarte

Carlos³

et al. 2019

Head & Neck

View full text Add to dashboard Cite

show abstract

“…This is because there are early data suggesting that men older than 26 years with anal HSIL may have a decreased risk of HSIL recurrence when they are given an adjuvant qHPV vaccine at the time of their HSIL treatment without the addition of any side effects. Others have reported similar evidence for decreasing rates of recurrent cervical intraepithelial neoplasia, vaginal intraepithelial neoplasia, and respiratory and laryngeal papillomatosis . Posttreatment adjuvant vaccination is not completely accepted in clinical practice because of the lack of randomized clinical trial data.…”

Section: Discussionmentioning

confidence: 97%

“…Others have reported similar evidence for decreasing rates of recurrent cervical intraepithelial neoplasia, vaginal intraepithelial neoplasia, and respiratory and laryngeal papillomatosis. [59][60][61][62][63][64][65][66] Posttreatment adjuvant vaccination is not completely accepted in clinical practice because of the lack of randomized clinical trial data. Furthermore, it is not understood whether the vaccine prevents the recurrence of the initially treated lesion or halts new HSIL development.…”

Section: Discussionmentioning

confidence: 99%

Management of precancerous anal intraepithelial lesions in human immunodeficiency virus–positive men who have sex with men: Clinical effectiveness and cost‐effectiveness

Deshmukh

Chiao

Cantor

et al. 2017

Cancer

View full text Add to dashboard Cite

BACKGROUND: Human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) are at disproportionately high risk for anal cancer. There is no definitive approach to the management of high-grade squamous intraepithelial lesions (HSIL), which are precursors of anal cancer, and evidence suggests that posttreatment adjuvant quadrivalent human papillomavirus (qHPV) vaccination improves HSIL treatment effectiveness. The objectives of this study were to evaluate the optimal HSIL management strategy with respect to clinical effectiveness and cost-effectiveness and to identify the optimal age for initiating HSIL management. METHODS: A decision analytic model of the natural history of anal carcinoma and HSIL management strategies was constructed for HIV-positive MSM who were 27 years old or older. The model was informed by the Surveillance, Epidemiology, and End Results-Medicare database and published studies. Outcomes included the lifetime cost, life expectancy, quality-adjusted life expectancy, cumulative risk of cancer and cancer-related deaths, and cost-effectiveness from a societal perspective. RESULTS: Active monitoring was the most effective approach in patients 29 years or younger; thereafter, HSIL treatment plus adjuvant qHPV vaccination became most effective. When cost-effectiveness was considered (ie, an incremental cost-effectiveness ratio [ICER] < $100,000/quality-adjusted life-year), do nothing was cost-effective until the age of 38 years, and HSIL treatment plus adjuvant qHPV vaccination was cost-effective beyond the age of 38 years (95% confidence interval, 34-43 years). The ICER decreased as the age at HSIL management increased. Outcomes were sensitive to the rate of HSIL regression or progression and the cost of high-resolution anoscopy and biopsy. CON-CLUSIONS: The management of HSIL in HIV-positive MSM who are 38 years old or older with treatment plus adjuvant qHPV vaccination is likely to be cost-effective. The conservative approach of no treatment is likely to be cost-effective in younger patients. Cancer 2017;123:4709-19.

show abstract

“…The 4vHPV vaccine, a highly successful prophylactic vaccine, [65][66][67] was licensed more than 8 y ahead of the 9vHPV vaccine. Therefore, the initial one or 2 doses (or even the full course of the 3-dose immunization) of the 4vHPV vaccine may have been administered before the availability of the 9vHPV vaccine.…”

Section: Use Of the 9vhpv Vaccine In Subjects Previously Vaccinated Wmentioning

confidence: 99%

Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine

Zhang

Xia

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Human papillomavirus is considered the causative factor for cervical cancer, which accounts for approximately 5% of the global cancer burden and more than 600,000 new cases annually that are attributable to HPV infection worldwide. The first-generation prophylactic HPV vaccines, Gardasil® and Cervarix®, were licensed approximately a decade ago. Both vaccines contain the most prevalent high-risk types, HPV16 and 18, which are associated with 70% of cervical cancer. To further increase the type coverage, 5 additional oncogenic HPV types (31, 33, 45, 52 and 58) were added to the existing Gardasil-4 to develop a 9-valent HPV vaccine (9vHPV), Gardasil 9®, increasing the potential level of protection from ∼70% to ∼90%. The efficacy of the vaccine lies primarily in its ability to elicit type-specific and neutralizing antibodies to fend off the viral infection. Therefore, type-specific and neutralizing murine monoclonal antibodies (mAbs) were used to quantitate the antigenicity of the individual vaccine antigens and to measure the antibody levels in the serum samples from vaccinees in a type- and epitope-specific manner in a competitive immunoassay. Assays for 9vHPV are extended from the proven platform used for 4vHPV by developing and adding new mAbs against the additional types. In Phase III clinical trials, comparable safety profile and immunogenicity against the original 4 types were demonstrated for the 9vHPV vaccine, and these were comparable to the 4vHPV vaccine. The efficacy of the 9vHPV vaccine was established in trials with young women. Immunobridging for younger boys and girls was performed, and the results showed higher immunogenicity in the younger age group. In a subsequent clinical trial, the 2-dose regimen of the 9vHPV vaccine used among girls and boys aged 9-14 y showed non-inferior immunogenicity to the regular 3-dose regimen for young women (aged 16-26 years). Overall, the clinical data and cost-effectiveness analysis for the 9vHPV vaccine support its widespread use to maximize the impact of this important, life-saving vaccine.

show abstract

Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis

Cited by 40 publications

References 22 publications

Histopathological features of juvenile‐onset laryngeal papillomatosis related to severity

Histopathological features of juvenile‐onset laryngeal papillomatosis related to severity

Management of precancerous anal intraepithelial lesions in human immunodeficiency virus–positive men who have sex with men: Clinical effectiveness and cost‐effectiveness

Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine

Contact Info

Product

Resources

About